FOR MORE INFORMATION: Company Contact: Jill Blumhoff Chief Financial Officer & Vice President of Finance Phone: 765.497.8381 jblumhoff@BASinc.com BASi Continues Revenue Growth in Second Quarter of Fiscal 2019

BASi Continues Revenue Growth

in Second Quarter of Fiscal 2019

WEST LAFAYETTE, IN, May

15, 2019 -- Bioanalytical Systems, Inc. (NASDAQ:BASI) ("BASi", the "Company", "We" or "Our")

today announced financial results for the three and six months ended March 31, 2019.

Robert Leasure, Jr., BASi's

President and Chief Executive Officer commented, "Our financial results have been in line with our expectations for fiscal

2019. This quarter we were able to recruit and fill open leadership and scientific team positions that are critical to meeting

the future expectations of our clients, employees and shareholders. We saw organic growth of 8% over the 1st quarter

of 2019 and overall growth of 58.7% so far over the first six months of 2018, including growth attributable to the Seventh Wave

acquisition. We have continued the integration process of the Seventh Wave acquisition, and on May 1, 2019, completed the acquisition

of Smithers Avanza's toxicology facility in Gaithersburg, Maryland. The new building expansion and facility improvements

in our Evansville facility continue to move forward. We obtained funding to support these initiatives and other improvements to

our facilities and equipment to support future growth and enhance our scientific capabilities and client experiences. We are proud

of the foundation we continue to build for the future."

Mr. Leasure continued, "We

continue to see our quoting activity and services backlog grow as a result of the acquisitions and investments into sales and marketing.

We plan to further develop our sales, marketing, client services and branding to drive revenue growth in the current year and beyond.

We will continue to develop existing services into "Centers of Excellence" to distinguish our services in the industry

and to evaluate additional opportunities for internal and external growth."

"Through all of our efforts,

we continue to emphasize and maintain a positive culture from which we can recruit and retain our talented team. The dedication

of the whole team to the Company and to our clients will continue to fuel our success with our initiatives," Mr. Leasure

Second Quarter Results

For the quarter, revenue amounted

to $9,344,000, a 60.4% increase from $5,944,000 in the second quarter of fiscal 2018. Revenue growth was mainly driven by the incremental

sales associated with the Seventh Wave acquisition, plus increased organic sales in both the Services and Products segments.

Net loss for the second quarter

of fiscal 2019 amounted to $569,000, or $0.06 per diluted share, compared to net income of $55,000, or $0.01 per diluted share

for the second quarter of fiscal 2018.

Net income and earnings per

share were impacted by the mix of revenues, recruiting and relocation of management team and growing the employee base, and higher

sales and marketing expenses. The higher sales and marketing expenses are driven by our focus on promoting our combined brand and

Adjusted EBITDA for the second

quarter of fiscal 2019, amounted to $273,000, compared to Adjusted EBITDA for the second quarter of fiscal 2018 of $524,000.

Second Quarter Segment Results

Service revenue for the second quarter

of fiscal 2019 increased 61.7% to $8,131,000 compared to $5,030,000 for the same period in fiscal 2018. Nonclinical services revenues

increased $2,486,000 due to an overall increase in the number of studies compared to the prior year period and additional revenues

attributable to the Seventh Wave Laboratories acquisition of $1,622,000 in the second quarter of fiscal 2019. Bioanalytical analysis

revenues increased by $638,000 in the second quarter of fiscal 2019, mainly due to additional revenues attributable to the Seventh

Wave Laboratories acquisition. Other laboratory services revenues were negatively impacted by lower archive revenues in the second

quarter of fiscal 2019 versus the comparable period in fiscal 2018.

Cost of Service revenue as a percentage

of Service revenue increased to 73.2% during the second quarter of fiscal 2019 from 72.8% in the comparable period in fiscal 2018.

The principal cause of this increase was due to the mix of services provided in the current quarter.

Sales in our Products segment increased

32.6% in the second quarter of fiscal 2019 from $914,000 to $1,213,000 when compared to the same period in the prior fiscal year.

The majority of the increase stems from higher sales of our Culex automated in vivo sampling systems and analytical instruments

in the current quarter as compared to the prior year quarter.

Cost of Products revenue as a percentage

of Products revenue in the second quarter of fiscal 2019 increased to 68.6% from 59.3% in the comparable prior-year period. This

increase is mainly due to higher material costs and the mix of product sales during the second quarter of fiscal 2019.

First Six Months' Results

For the first six months of

fiscal 2019, revenue amounted to $17,969,000, a 58.7% increase from $11,321,000 in the first half of fiscal 2018. Revenue growth

was mainly driven by incremental sales associated with the Seventh Wave acquisition plus increased sales in both the Services and

Net loss for the first six months

of fiscal 2019 amounted to $654,000, or $0.06 per diluted share, compared to net income of $81,000, or $0.01 per diluted share

for the first six months of fiscal 2018.

Net income and earnings per

share were impacted by recruiting and bringing on new employees, the mix of revenues and higher sales and marketing expenses. The

higher sales and marketing expenses are driven by our focus on promoting our combined brand and revenue growth.

Adjusted EBITDA for the first

six months of fiscal 2019, amounted to $1,173,000, compared to Adjusted EBITDA for the first six months of fiscal 2018 of $969,000.

First Six Months' Segment

Service revenue for the first six months

of fiscal 2019 increased 66.0% to $15,866,000 compared to $9,555,000 for the same period in fiscal 2018. Nonclinical services revenues

increased $4,963,000 due to an overall increase in the number of studies compared to the prior year period and additional revenues

attributable to the Seventh Wave Laboratories acquisition of $3,547,000 in the first six months of fiscal 2019. Bioanalytical analysis

revenues increased by $1,314,000 in the first six months of fiscal 2019, mainly due to additional revenues attributable to the

Seventh Wave Laboratories acquisition. Other laboratory services revenues were positively impacted by higher pharmaceutical analysis

revenues in the first six months of fiscal 2019 versus the comparable period in fiscal 2018.

Cost of Service revenue as a percentage

of Service revenue increased to 72.8% during the first six months of fiscal 2019 from 72.6% in the comparable period in fiscal

2018. The principal cause of this increase was due to the mix of services provided in the first six months of fiscal 2019.

Sales in our Products segment increased

19.0% in the first six months of fiscal 2019 from $1,766,000 to $2,103,000 when compared to the same period in the prior fiscal

year. The majority of the increase stems from higher sales of our Culex automated in vivo sampling systems and analytical instruments

in the current period as compared to the prior year period.

Cost of Products revenue as a percentage

of Products revenue in the first six months of fiscal 2019 increased to 68.5% from 60.3% in the comparable prior-year period. This

increase is mainly due to higher material costs and the mix of product sales during the first six months of fiscal 2019.

Cash Provided by Operating Activities

Cash provided by operating activities was

$911,000 for the first six months of fiscal 2019 compared to $842,000 for the same period in fiscal 2018.

As of March 31, 2019, the Company had $520,000

in cash and cash equivalents, a $409,000 balance on its general line of credit, a $908,000 balance on its $4,445,000 construction

line of credit and a $285,000 balance on its $1,429,250 equipment line of credit. During fiscal 2019, cash from operations, cash

on hand and financing activities funded capital expenditures of approximately $2,218,000 for the expansion of our Evansville facility

in addition to laboratory equipment and building improvements as well as computer equipment and software.

On May 1, 2019, the Company acquired from

Smithers Avanza Toxicology Services LLC ("Seller"), a consulting-based contract research laboratory located in Gaithersburg,

Maryland, substantially all of the assets used by the Seller in connection with the performance of in-vivo mammalian toxicology

CRO services for pharmaceuticals (small molecules and biologics), vaccines, agro and industrial chemicals, under the terms and

conditions of an Asset Purchase Agreement, dated May 1, 2019. The consideration for the Acquisition consisted of $1,270,646.10

in cash, subject to certain adjustments, 200,000 of the Company's common shares and an unsecured promissory note in the initial

principal amount of $810,000. The Company funded the cash portion of the purchase price for the Acquisition with cash on hand and

the net proceeds from the refinancing of its credit arrangements with First Internet Bank ("FIB").